Ghrelin Receptor Agonist

Ibutamoren (MK-677)

4.9/10

BioHarmony verdict

Neutral

MK-677 (ibutamoren) is an oral, once-daily growth-hormone secretagogue that raises IGF-1 by about 50 to 97 percent and adds roughly 1.1 kg of fat-free mass, per the Nass 2008 two-year trial, but it also raises fasting glucose and never won FDA approval.

Read full report

What is Ibutamoren (MK-677)?

MK-677, also called ibutamoren, is an oral, once-daily growth-hormone secretagogue that lands at 4.5-5.0/10, Neutral, because its real strengths and real harms almost perfectly cancel out. It works by activating the ghrelin receptor, which nudges your own pituitary to release more growth hormone and raises IGF-1 into the young-adult range, per Patchett 1995. What makes it stand out from the injectable peptides people compare it to is the evidence behind it. It has been through multiple double-blind, placebo-controlled human trials, including a 2-year study and a 563-patient pivotal trial. That is far more human data than most things in this category have.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Agonist at the growth-hormone-secretagogue receptor (GHS-R1a), the same receptor ghrelin uses

Safety watch-outs

  • Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes or pre-diabetes.
  • New edema or any breathlessness, ankle swelling, or unusual fatigue: stop, given the documented congestive-heart-failure signal.
  • Any active or suspected cancer: do not use, because growth-hormone and IGF-1 signaling can promote proliferation.
  • Carpal-tunnel-type numbness or tingling that worsens: reduce the dose or stop.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Ibutamoren (MK-677) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingFDA Category 2 for 503A and 503B use
Last checked2026-07-13
Next review2026-10-11

FDA places ibutamoren mesylate in Category 2 for 503A and 503B compounding and identifies a potential congestive-heart-failure safety signal.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.